Ataluren
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amino Acid Metabolism, Inborn Errors
Conditions
Amino Acid Metabolism, Inborn Errors
Trial Timeline
Jul 19, 2010 → Nov 3, 2011
NCT ID
NCT01141075About Ataluren
Ataluren is a phase 2 stage product being developed by Sanofi for Amino Acid Metabolism, Inborn Errors. The current trial status is terminated. This product is registered under clinical trial identifier NCT01141075. Target conditions include Amino Acid Metabolism, Inborn Errors.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01141075 | Phase 2 | Terminated |
| NCT00947193 | Phase 2 | Terminated |
| NCT00847379 | Phase 2 | Terminated |
| NCT00759876 | Phase 2 | Terminated |
Competing Products
4 competing products in Amino Acid Metabolism, Inborn Errors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Acetaminophen | Johnson & Johnson | Approved | 85 |
| Intravenous infusion of N-acetylcysteine + Intravenous infusion of Fomepizole (4-MP) | Johnson & Johnson | Phase 2 | 52 |
| AAV2-hAADC | PTC Therapeutics | Phase 2 | 49 |
| gene therapy | PTC Therapeutics | Phase 1/2 | 38 |